Skip to main content
SpringerLink
Log in

Synthesis, characterization and biodistribution of 99mTc-Bioquin-HMPAO (99mTc-BH) as a novel brain imaging agent

  • Published:
Journal of Radioanalytical and Nuclear Chemistry Aims and scope Submit manuscript

Abstract

Recently, the development of novel brain imaging agents has aroused much interest thanks to limited number of brain cancer or diseases diagnosis agents. It is aimed to synthesize a novel brain imaging agent including a promise for further studies on AD diagnosis potential and investigate its bioaffinity with biodistribution studies on healthy Balb/c mice. A novel radiolabeled agent was synthesized and characterized. Quality control of 99mTc-BH was performed utilizing solvent extraction and chromatographic (Radio TLC and Radio HPLC) methods. Bioaffinity of the 99mTc-BH was investigated on male Balb/c mice at various time points (5, 30, 60, 120 min post-injection). Paper electrophoresis showed that 99mTc-BH has a neutral structure. Radiochemical purity of 99mTc-BH was over 95 % with appropriate stability for imaging period. Selected brain regions have uptakes over 4 % ID/g following intravenous injection. Hippocampus has uptake approximately 10 % ID/g. 99mTc-BH has shown brain uptake, so it may prove to be valuable for brain imaging as a novel technetium-labeled agent. Further investigations with AD animal model are our on going effort to show that this agent has AD diagnosis potential.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Mathis CA, Wang Y, Klunk WE (2004) Imaging beta-amyloid plaques and neurofibrillary tangles in the aging human brain. Curr Pharm Des 10:1469–1492

    Article  CAS  Google Scholar 

  2. Association A (2013) Alzheimer’s disease facts and figures. Alzheimer’s Dement 9:208–276

    Article  Google Scholar 

  3. Fodero-Tavoletti MT, Cappai R, McLean CA, Pike KE, Adlard PA, Cowie T, Connor AR, Masters CL, Rowe CC, Villemagne VL (2009) Amyloid imaging in Alzheimer’s disease and other dementias. Brain Imaging Behav 3:246–261

    Article  Google Scholar 

  4. Nakamura S, Murayama N, Noshita T, Annoura H, Ohno T (2001) Progressive brain dysfunction following intracerebroventricular infusion of beta(1-42)-amyloid peptide. Brain Res 912:128–136

    Article  CAS  Google Scholar 

  5. Wei J, Wu C, Lankin D, Gulrati A, Valyi-Nagy T, Cochran E, Pike VW, Kozikowski A, Wang Y (2005) Development of novel amyloid imaging agents based upon thioflavin S. Curr Alzheimer Res 2:109–114

    Article  CAS  Google Scholar 

  6. Relkin NR (2008) Testing the mettle of PBT2 for Alzheimer’s disease. Lancet Neurol 7:762–763

    Article  Google Scholar 

  7. Palmer AM (2011) Neuroprotective therapeutics for Alzheimer’s disease: progress and prospects. Trends Pharmacol Sci 32:141–147

    Article  CAS  Google Scholar 

  8. Kung M-P, Hou C, Zhuang Z-P, Skovronsky D, Kung HF (2004) Binding of two potential imaging agents targeting amyloid plaques in postmortem brain tissues of patients with Alzheimer’s disease. Brain Res 1025:98–105

    Article  CAS  Google Scholar 

  9. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356

    Article  CAS  Google Scholar 

  10. Kulkarni PV, Roney CA, Antich PP, Bonte FJ, Raghu AV, Aminabhavi TM (2010) Quinoline-n-butylcyanoacrylate-based nanoparticles for brain targeting for the diagnosis of Alzheimer’s disease. WIREs Nanomed Nanobiotechnol 2:35–47

    Article  CAS  Google Scholar 

  11. Nordberg A (2004) Reviews PET imaging of amyloid in Alzheimer’s disease. Lancet Neurol 3:519–527

    Article  CAS  Google Scholar 

  12. Zhen W, Han H, Anguiano M, Lemere CA, Cho CG, Lansbury PT (1999) Synthesis and amyloid binding properties of rhenium complexes: preliminary progress toward a reagent for SPECT imaging of Alzheimer’s disease brain. J Med Chem 42:2805–2815

    Article  CAS  Google Scholar 

  13. Pirmettis IC, Papadopoulos MS, Chiotellis E (1997) Novel 99mTc amino bisthiolato/monothiolato “3 + 1″ mixed ligand complexes: structure-activity relationships and preliminary in vivo validation as brain blood flow imaging agents. J Med Chem 40:2539–2546

    Article  CAS  Google Scholar 

  14. Opazo C, Luza S, Villemagne VL, Volitakis I, Rowe C, Barnham KJ, Strozyk D, Masters CL, Cherny RA, Bush AI (2006) Radioiodinated clioquinol as a biomarker for beta-amyloid: zn complexes in Alzheimer’s disease. Aging Cell 5:69–79

    Article  CAS  Google Scholar 

  15. McColl G, Roberts BR, Pukala TL, Kenche VB, Robets CM, Link CD, Ryan TM, Masters CL, Barnham KJ, Bush AI, Cherny RA (2012) Utility of an improved model of amyloid-beta (Aβ1_42) toxicity in Caenorhabditis elegans for drug screening for Alzheimer’s disease. Mol Neurodegener 7:57–65

    Article  CAS  Google Scholar 

  16. Faux NG, Ritchie CW, Gunn A, Rembach A, Tsatsanis A, Bedo J, Harrison J, Lannfelt L, Blennow K, Zetterberg H, Ingelsson M, Masters CL, Tanzi RE, Cummings JL, Herd CM, Bush AI (2010) PBT2 rapidly improves cognition in Alzheimer’s Disease: additional phase II analyses. J Alzheimers Dis 20:509–516

    CAS  Google Scholar 

  17. Adlard PA, Cherny RA, Finkelstein DI, Gautier E, Robb E, Cortes M, Volitakis I, Liu X, Smith JP, Perez K, Laughton K, Li Q-X, Charman SA, Nicolazzo JA, Wilkins S, Deleva K, Lynch T, Kok G, Ritchie CW, Tanzi RE, Cappai R, Masters CL, Barnham KJ, Bush AI (2008) Rapid restoration of cognition in Alzheimer’s transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 59:43–55

    Article  CAS  Google Scholar 

  18. Mirahmadi N, Babaei MH, Vali AM, Daha FJ, Kobarfard F, Dadashzadeh S (2008) 99mTc-HMPAO-labeled liposomes: an investigation into the effects of some formulation factors on labeling efficiency and in vitro stability. Nucl Med Biol 35:387–392

    Article  CAS  Google Scholar 

  19. Mele’ndez-Alafort LM, Riondato M, Nadali A, Banzato A, Camporese D, Boccaccio P, Uzunov N, Rosato A, Mazzi U (2006) Bioavailability of 99mTc-Ha-paclitaxel complex [99mTc-ONCOFID-P] in mice using four different administration routes. J Label Compd Radiopharm 49:939–950

    Article  Google Scholar 

  20. Zolle I (2007) Technetium-99m Pharmaceuticals Preparation and Quality. 173–337

  21. Meek WH, Fuchsman CH (1969) Carboxylation of substituted phenols in N, N-dimethylamide solvents at atmospheric pressure. J Chem Eng Data 14:388–391

    Article  CAS  Google Scholar 

  22. Mouscadet J-F, Desmaële D (2010) Chemistry and structure-activity relationship of the styrylquinoline-type HIV integrase inhibitors. Molecules 15:3048–3078

    Article  CAS  Google Scholar 

  23. Ballinger JR, Duncan J, Hua AH, Ichise M (1997) Accumulation of 99mTc-HMPAO and 99mTc-ECD in rodent and human breast tumor cell lines in vitro. Ann Nucl Med 11:95–99

    Article  CAS  Google Scholar 

  24. Chattopadhyay S, Das MK, Vanaja R, Ramamoorthy N (2001) Purification and stabilization of 99mTc-d, l-HMPAO: role of organic extractants. Nucl Med Biol 28:741–744

    Article  CAS  Google Scholar 

  25. Huang W, Yao H, Lo J (2004) Preparation and Biolocalization of Technetium-99m Complexes with N2O2 Schiff-Base Compounds. Ann Nucl Med Sci 17:13–19

    Google Scholar 

  26. Lo J, Huang W, Kao C, Yang C (2001) Mechanism of 99mTc-d, l-HMPAO retention in brain cells. Ann Nucl Med Sci 14:215–222

    Google Scholar 

  27. Neirinckx RD, Canning LR, Piper IM, Nowotnik DP, Pickett RD, Holmes RA, Volkert WA, Forster AM, Weisner PS, Marriott JA, Chaplin SB (1987) Technetium-99m d, l-HM-PAO: a new radiopharmaceutical for SPECT imaging of regional cerebral blood perfusion. J Nucl Med 28:191–202

    CAS  Google Scholar 

  28. Roney C, Kulkarni P, Arora V, Antich P, Bonte F, Wu A, Mallikarjuana NN, Manohar S, Liang H-F, Kulkarni AR, Sung H-W, Sairam M, Aminabhavi TM (2005) Targeted nanoparticles for drug delivery through the blood-brain barrier for Alzheimer’s disease. J Control Release 108:193–214

    Article  CAS  Google Scholar 

  29. Schwochau K (2000) Technetium Chemistry and Radiopharmaceutical Applications. 1–460

  30. Dischino DD, Welch JM, Kilbourn RM, Raichle EM (1983) Relationship Between Lipophilicity and Brain Extraction of C-11-Radiopharmaceuticals. J Nucl Med 24:1030–1038

    CAS  Google Scholar 

  31. Fritzberg AR, Lyster DM, Dolphin DH (1976) 99mTc-bioquin-7CA, a potential new hepatobiliary scanning agent. J Nucl Med 17:907–910

    CAS  Google Scholar 

  32. Zhang J-F, Qi J-S, Qiao J-T (2009) Protein kinase C mediates amyloid beta-protein fragment 31-35-induced suppression of hippocampal late-phase long-term potentiation in vivo. Neurobiol Learn Mem 91:226–234

    Article  CAS  Google Scholar 

  33. West MJ, Kawas CH, Martin LJ, Troncoso JC (2006) The CA1 Region of the Human Hippocampus Is a Hot Spot in Alzheimer’s Disease. Ann N Y Acad Sci 908:255–259

    Article  Google Scholar 

  34. Nebu A, Ikeda M, Fukuhara R, Komori K, Maki N, Hokoishi K, Shigenobu K, Kikuchi T, Tanabe H (2001) Utility of 99mTc-HM-PAO SPECT hippocampal image to diagnose early stages of Alzheimer’s Disease using semiquantitative analysis. Dement Geriatr Cogn Disord 12:153–157

    Article  CAS  Google Scholar 

  35. Roney CA, Arora V, Kulkarni PV, Antich PP, Bonte FJ (2009) Nanoparticulate radiolabelled quinolines detect amyloid plaques in mouse models of Alzheimer’s disease. Int J Alzheimers Dis 2009:1–8

    Article  Google Scholar 

Download references

Acknowledgments

This work is supported by Ege University Research Fund (contract no 2011 NBE 003). The authors thank to Eser Uçar, Cansu Uzaras, Kadir Arı and Barış Yılmaz for the technical assistance during the animal experiments.

Author information

Authors and Affiliations

  1. Department of Nuclear Applications, Institute of Nuclear Sciences, Ege University, 35100, Bornova, Izmir, Turkey

    Ayfer Yurt Kilcar, Fazilet Zumrut Biber Muftuler, Volkan Tekin, Emin Ilker Medine & Perihan Unak

  2. Department of Chemistry, Afyon Kocatepe University, Afyon, Turkey

    Huseyin Enginar

Authors
  1. Ayfer Yurt Kilcar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fazilet Zumrut Biber Muftuler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Huseyin Enginar
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Volkan Tekin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Emin Ilker Medine
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Perihan Unak
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Fazilet Zumrut Biber Muftuler.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yurt Kilcar, A., Biber Muftuler, F.Z., Enginar, H. et al. Synthesis, characterization and biodistribution of 99mTc-Bioquin-HMPAO (99mTc-BH) as a novel brain imaging agent. J Radioanal Nucl Chem 302, 563–573 (2014). https://doi.org/10.1007/s10967-014-3175-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10967-014-3175-1

Keywords

Search

Navigation